Subcutaneous Immune Globulin Hizentra Available in 10g Prefilled Syringe

Hizentra^® (immune globulin subcutaneous [human] 20% Liquid) is now available in a new 10g/50mL prefilled syringe.

Hizentra is indicated:

• As replacement therapy for primary immunodeficiency (PI) in adults and pediatric patients 2 years of age and older (eg, congenital or X-linked agammaglobulinemia, common variable immunodeficiency, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies). 
• As maintenance therapy to prevent relapse of neuromuscular disability and impairment in adults with chronic inflammatory demyelinating polyneuropathy (CIDP).

“The availability of the 10g prefilled syringe is CSL Behring’s latest development in helping the rare disease community effectively manage PI and CIDP, as some patients may require treatment at a higher volume,” said Bob Lojewski, Senior Vice President and General Manager, North America, CSL Behring. 

Hizentra is also available in 1g/5mL, 2g/10mL, and 4g/20mL prefilled syringes as well as in 1g/5mL, 2g/10mL, 4g/20mL, and 10g/50mL vials.